source
- Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goalTaiho Pharmaceutical and Cullinan Therapeutics have celebrated a second phase 3 victory for their small-molecule EGFR inhibitor, teeing the partners up to challenge Johnson & Johnson for a lung can…Fierce Biotech · 8h ago↗ source
- Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decisionAs the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.Fierce Biotech · 8h ago↗ source
- Medtronic veteran Bill Shields crosses over to become CEO at valve disease startupAfter 15 years with Medtronic’s structural heart franchise, Bill Shields is leaving the medtech giant to become the chief executive of startup Versa Vascular.